DK3024463T3 - Neuroprotektive bicykliske forbindelser og fremgangsmåder til deres anvendelse til behandling af autismespektrumforstyrrelser og neurodevelopmentale forstyrrelser - Google Patents
Neuroprotektive bicykliske forbindelser og fremgangsmåder til deres anvendelse til behandling af autismespektrumforstyrrelser og neurodevelopmentale forstyrrelser Download PDFInfo
- Publication number
- DK3024463T3 DK3024463T3 DK14829224.6T DK14829224T DK3024463T3 DK 3024463 T3 DK3024463 T3 DK 3024463T3 DK 14829224 T DK14829224 T DK 14829224T DK 3024463 T3 DK3024463 T3 DK 3024463T3
- Authority
- DK
- Denmark
- Prior art keywords
- disorders
- spectric
- relations
- procedures
- treating autism
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/499—Spiro-condensed pyrazines or piperazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361958329P | 2013-07-25 | 2013-07-25 | |
| PCT/US2014/047801 WO2015013397A2 (en) | 2013-07-25 | 2014-07-23 | Neuroprotective bicyclic compounds and methods for their use in treating autism spectrum disorders and neurodevelopmental disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3024463T3 true DK3024463T3 (da) | 2020-06-29 |
Family
ID=52393968
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK14829224.6T DK3024463T3 (da) | 2013-07-25 | 2014-07-23 | Neuroprotektive bicykliske forbindelser og fremgangsmåder til deres anvendelse til behandling af autismespektrumforstyrrelser og neurodevelopmentale forstyrrelser |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US9867823B2 (da) |
| EP (1) | EP3024463B1 (da) |
| JP (1) | JP6574769B2 (da) |
| CY (1) | CY1123058T1 (da) |
| DK (1) | DK3024463T3 (da) |
| ES (1) | ES2797374T3 (da) |
| HR (1) | HRP20201002T1 (da) |
| HU (1) | HUE049302T2 (da) |
| LT (1) | LT3024463T (da) |
| PL (1) | PL3024463T3 (da) |
| PT (1) | PT3024463T (da) |
| RS (1) | RS60679B1 (da) |
| SI (1) | SI3024463T1 (da) |
| WO (1) | WO2015013397A2 (da) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109562110A (zh) * | 2016-05-26 | 2019-04-02 | 株式会社日本阿明诺化学 | 睡眠改善剂 |
| RU2021106383A (ru) | 2016-08-24 | 2021-04-05 | Зодженикс Интернэшнл Лимитед | Состав для ингибирования образования агонистов 5-ht2b и способы его применения |
| US10467828B2 (en) * | 2017-03-06 | 2019-11-05 | J. J. Keller & Associates, Inc. | Electronic logging device |
| WO2019045575A1 (en) * | 2017-08-28 | 2019-03-07 | Vitality Wellness (Nz) Limited | IMPROVEMENTS IN IGF-1 ANALYSIS, ADJUSTMENT AND DISEASE MANAGEMENT IN NON-NEUROLOGICAL AND / OR NEUROLOGICAL STATES |
| US20190091179A1 (en) * | 2017-09-26 | 2019-03-28 | Zogenix International Limited | Congnitive function with fenfluramine |
| WO2019082125A1 (en) * | 2017-10-27 | 2019-05-02 | Amo Pharma Ltd. | METHODS OF TREATING PHELAN MCDERMID SYNDROME USING FARNESYL-DIBENZODIAZEPINONES |
| JP6598412B1 (ja) * | 2019-06-04 | 2019-10-30 | ゼライス株式会社 | 認知機能改善用食品 |
| BR112022007636A2 (pt) * | 2019-10-22 | 2022-07-12 | Neuren Pharmaceuticals Ltd | Compostos bicíclicos e métodos para seus usos no tratamento da síndrome de pitt-hopkins |
| AU2020376801A1 (en) * | 2019-10-28 | 2022-06-09 | Acadia Pharmaceuticals Inc. | Methods and compositions for treatment of Rett syndrome |
| CN113243332B (zh) * | 2020-02-07 | 2023-07-28 | 上海市东方医院（同济大学附属东方医院） | 一种广泛脑区神经元树突发育障碍动物模型的制备与应用 |
| AU2022316209A1 (en) | 2021-07-20 | 2024-02-22 | Regeneron Pharmaceuticals, Inc. | Butyrophilin-like 2 agents for treating inflammatory disorders |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4511390A (en) | 1983-06-10 | 1985-04-16 | E. I. Du Pont De Nemours And Company | Aralkylcarbamoyl peptide alcohols |
| DE3502041A1 (de) | 1985-01-23 | 1986-07-24 | Grünenthal GmbH, 5190 Stolberg | Verwendung von dipeptidderivaten zur behandlung posttraumatischer nervenschaeden |
| EP1033128B2 (en) * | 1993-09-28 | 2011-11-23 | R.P. Scherer GmbH | Soft gelatin capsule manufacture |
| US5686423A (en) | 1996-02-16 | 1997-11-11 | Department Of Health, The Executive Yuan, Republic Of China | Di-and tri-peptide mimetic compounds for Parkinson's disease |
| WO2001002405A1 (en) | 1999-07-06 | 2001-01-11 | Vertex Pharmaceuticals Incorporated | Quinuclidine derivatives for treatment of neurological disorders |
| US7714020B2 (en) | 2001-05-24 | 2010-05-11 | Neuren Pharmaceuticals Limited | Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate |
| US20100247483A1 (en) * | 2001-11-13 | 2010-09-30 | Tran Loi H | Therapeutic agent composition and method of use |
| UA77515C2 (en) * | 2002-04-04 | 2006-12-15 | Diazabicyclo alkane derivatives possessing neuroldnin-nk1 receptor antagonistic activity | |
| US8791117B2 (en) * | 2003-09-03 | 2014-07-29 | Neuren Pharmaceuticals Limited | Cyclic glycyl-2-allyl proline improves cognitive performance in impaired animals |
| ES2564803T3 (es) | 2003-09-03 | 2016-03-29 | Neuren Pharmaceuticals Limited | Compuestos neuroprotectores bicíclicos y composiciones farmacéuticas que los contienen |
| WO2005120496A2 (en) * | 2004-05-24 | 2005-12-22 | Regents Of The University Of California | TREATING LEARNING DEFICITS WITH INHIBITORS OF HMG CoA REDUCTASE |
| US20070199096A1 (en) | 2005-11-14 | 2007-08-23 | E.I. Du Pont De Nemours And Company | Compositions and Methods for Altering Alpha- and Beta-Tocotrienol Content |
| JP5220724B2 (ja) * | 2006-03-14 | 2013-06-26 | ニューレン ファーマシューティカルズ リミテッド | グリシル−２−メチルプロリルグルタミン酸塩の経口製剤 |
| AU2011223706A1 (en) * | 2010-03-05 | 2012-09-20 | Baylor Research Institute | Involvement of androgen/androgen receptor pathway in Fabry disease |
| EP2571515B1 (en) | 2010-05-17 | 2016-11-30 | Icahn School of Medicine at Mount Sinai | Methods and assays for treating subjects with shank3 deletion, mutation or reduced expression |
| DK2667715T3 (da) * | 2011-01-27 | 2017-10-23 | Neuren Pharmaceuticals Ltd | Behandling af autismespektrumforstyrrelser ved anvendelse af glycyl-l-2-methylprolyl-l-glutaminsyre |
-
2014
- 2014-07-23 WO PCT/US2014/047801 patent/WO2015013397A2/en active Application Filing
- 2014-07-23 HU HUE14829224A patent/HUE049302T2/hu unknown
- 2014-07-23 RS RS20200716A patent/RS60679B1/sr unknown
- 2014-07-23 ES ES14829224T patent/ES2797374T3/es active Active
- 2014-07-23 PL PL14829224T patent/PL3024463T3/pl unknown
- 2014-07-23 PT PT148292246T patent/PT3024463T/pt unknown
- 2014-07-23 DK DK14829224.6T patent/DK3024463T3/da active
- 2014-07-23 EP EP14829224.6A patent/EP3024463B1/en active Active
- 2014-07-23 LT LTEP14829224.6T patent/LT3024463T/lt unknown
- 2014-07-23 SI SI201431598T patent/SI3024463T1/sl unknown
- 2014-07-23 JP JP2016529857A patent/JP6574769B2/ja active Active
-
2016
- 2016-01-22 US US15/004,218 patent/US9867823B2/en active Active
-
2018
- 2018-01-12 US US15/869,672 patent/US10548892B2/en active Active
-
2020
- 2020-01-22 US US16/749,185 patent/US11197856B2/en active Active
- 2020-06-17 CY CY20201100552T patent/CY1123058T1/el unknown
- 2020-06-25 HR HRP20201002TT patent/HRP20201002T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3024463A4 (en) | 2017-03-01 |
| JP2016525547A (ja) | 2016-08-25 |
| SI3024463T1 (sl) | 2020-08-31 |
| EP3024463B1 (en) | 2020-03-25 |
| US20170020869A1 (en) | 2017-01-26 |
| PT3024463T (pt) | 2020-06-30 |
| ES2797374T3 (es) | 2020-12-02 |
| WO2015013397A2 (en) | 2015-01-29 |
| PL3024463T3 (pl) | 2020-10-05 |
| LT3024463T (lt) | 2020-07-10 |
| US10548892B2 (en) | 2020-02-04 |
| US9867823B2 (en) | 2018-01-16 |
| EP3024463A2 (en) | 2016-06-01 |
| JP6574769B2 (ja) | 2019-09-11 |
| CY1123058T1 (el) | 2021-10-29 |
| RS60679B1 (sr) | 2020-09-30 |
| US20200163961A1 (en) | 2020-05-28 |
| US20180140601A1 (en) | 2018-05-24 |
| WO2015013397A3 (en) | 2015-04-30 |
| US11197856B2 (en) | 2021-12-14 |
| HRP20201002T1 (hr) | 2020-10-16 |
| HUE049302T2 (hu) | 2020-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3024463T3 (da) | Neuroprotektive bicykliske forbindelser og fremgangsmåder til deres anvendelse til behandling af autismespektrumforstyrrelser og neurodevelopmentale forstyrrelser | |
| DK3035926T3 (da) | Forbindelser og fremgangsmåder til behandling af en epilepsilidelse | |
| DK3060237T3 (da) | Modificeret omprogrammeringsprotein til anvendelse i behandling af cancer | |
| DK2838900T3 (da) | Forbindelser og fremgangsmåder til antiviral behandling | |
| DK3088353T3 (da) | Bilirubinpartikler og deres fremstilling til anvendelse i terapi | |
| DK2969479T3 (da) | Væskeanordninger i flere lag og fremgangsmåder til deres fremstilling | |
| DK3019483T3 (da) | Terapeutiske aktive forbindelser og fremgangsmåder til deres anvendelse | |
| DK3083616T3 (da) | Bicykliske heterocykliske forbindelser og disses anvendelser i terapi | |
| DK2943192T3 (da) | Fremgangsmåder til behandling af pancreascancer, hvilke fremgangsmåder omfatter paclitaxel og gemcitabin | |
| DK3076972T3 (da) | Cancerbehandling med kombination af plinabulin og taxan | |
| DK3811943T3 (da) | Forbindelse til anvendelse til behandling af øjenlidelser | |
| DK3395354T3 (da) | Plasminogen til anvendelse i behandling af diabetisk nefropati | |
| DK2815769T3 (da) | Fam19a5 til anvendelse i diagnosticering og behandling af skader på centralnervesystemet | |
| DK3049056T3 (da) | Topisk antisvampesammensætning og fremgangsmåder til behandling | |
| DK3076976T3 (da) | Fremgangsmåder til behandling af cancer | |
| DK3054976T3 (da) | Anvendelse af semaphorin-4d-bindende molekyler til behandling af aterosklerose | |
| DK2962100T3 (da) | Tuberkulosebiomarkører og anvendelser deraf | |
| DK2994533T3 (da) | Fremgangsmåder og sammensætninger til behandling af cancer | |
| DK2964767T3 (da) | Toksingener og fremgangsmåder til anvendelse deraf | |
| EP3057689A4 (en) | POLYMERIC MEMBRANES TREATED BY ULTRAVIOLET AND THERMALLY RADIATION | |
| DK3033081T3 (da) | Sammensætninger og fremgangsmåder til behandling af kronisk urticaria | |
| HK1219511A1 (zh) | 納米流體中分子的表徵 | |
| DK3058936T3 (da) | Peptidsammensætning og anvendelser deraf | |
| DK2994157T3 (da) | Tafa4-forbindelser og anvendelser deraf til behandling af smerte | |
| DK2984184T3 (da) | Anvendelse af dnq eller dnq-87 i kombination med en parp1-inhibitor til behandlingen af cancer |